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Pre-existing polymerase-specific T cells 
expand in abortive seronegative SARS-CoV-2
 
Leo Swadling1 ✉, Mariana O. Diniz1,24, Nathalie M. Schmidt1,24, Oliver E. Amin1,24, 
Aneesh Chandran1,24, Emily Shaw1,24, Corinna Pade2, Joseph M. Gibbons2, Nina Le Bert3, 
Anthony T. Tan3, Anna Jeffery-Smith1,2, Cedric C. S. Tan4, Christine Y. L. Tham3, 
Stephanie Kucykowicz1, Gloryanne Aidoo-Micah1, Joshua Rosenheim1, Jessica Davies1, 
Marina Johnson5, Melanie P. Jensen6,7, George Joy6,8, Laura E. McCoy1, Ana M. Valdes9,10, 
Benjamin M. Chain1, David Goldblatt5, Daniel M. Altmann11, Rosemary J. Boyton12,13, 
Charlotte Manisty6,8, Thomas A. Treibel6,8, James C. Moon6,8, COVIDsortium investigators*, 
Lucy van Dorp4, Francois Balloux4, Áine McKnight2, Mahdad Noursadeghi1,24, 
Antonio Bertoletti3,14,24 & Mala K. Maini1 ✉
Individuals with potential exposure to SARS-CoV-2 do not necessarily develop PCR or 
antibody positivity, suggesting some may clear sub-clinical infection before 
seroconversion. T-cells can contribute to the rapid clearance of SARS-CoV-2 and 
other coronavirus infections1–3. We hypothesised that pre-existing memory T-cell 
responses, with cross-protective potential against SARS-CoV-24–11, would expand 
in vivo to support rapid viral control, aborting infection. We measured SARS-CoV-
2-reactive T-cells, including those against the early transcribed replication 
transcription complex (RTC)12,13, in intensively monitored healthcare workers (HCW) 
remaining repeatedly negative by PCR, antibody binding, and neutralisation 
(seronegative HCW, SN-HCW). SN-HCW had stronger, more multispecific memory 
T-cells than an unexposed pre-pandemic cohort, and more frequently directed 
against the RTC than the structural protein-dominated responses seen 
post-detectable infection (matched concurrent cohort). SN-HCW with the strongest 
RTC-specific T-cells had an increase in IFI27, a robust early innate signature of 
SARS-CoV-214, suggesting abortive infection. RNA-polymerase within RTC was the 
largest region of high sequence conservation across human seasonal coronaviruses 
(HCoV) and SARS-CoV-2 clades. RNA-polymerase was preferentially targeted 
(amongst regions tested) by T-cells from pre-pandemic cohorts and SN-HCW. RTC 
epitope-specific T-cells cross-recognising HCoV variants were identified in SN-HCW. 
Enriched pre-existing RNA-polymerase-specific T-cells expanded in vivo to 
preferentially accumulate in the memory response after putative abortive compared 
to overt SARS-CoV-2 infection. Our data highlight RTC-specific T-cells as targets for 
vaccines against endemic and emerging Coronaviridae.
There is wide variability in the outcome of exposure to SARS-CoV-2, 
ranging from severe illness to asymptomatic infection, to those 
remaining negative with standard diagnostic tests. Recent studies 
have identified SARS-CoV-2 T-cell reactivity in pre-pandemic sam-
ples5–11,15–18 and isolated cases of exposed individuals who have not 
seroconverted with single time point screening4,16,19–22. We studied an 
intensively monitored cohort of HCW with potential exposure during 
the first UK pandemic wave, comparing those with or without PCR 
and/or antibody evidence of SARS-CoV-2 infection. We postulated 
that in HCW where PCR, and the most sensitive binding and neutral-
ising antibody (nAb) tests, remained repeatedly negative (SN-HCW), 
T-cell assays might distinguish a subset with a subclinical, rapidly 
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terminated (abortive) infection. We hypothesised that these indi-
viduals would exhibit pre-existing memory T-cells with cross-reactive 
potential, obviating the time required for de novobefore, or at the time 
of, potential exposure.
We included analysis of the understudied T-cells directed against 
the core RTC within open reading frame (ORF)1ab (RNA-polymerase 
co-factor non-structural protein 7 [NSP7], RNA-polymerase NSP12, 
and helicase NSP13, henceforth referred to as RTC); these are putative 
targets for pre-existing responses with pan-Coronaviridae reactivity, 
because they are likely to be highly conserved due to their key early 
roles in the viral life cycle. Consistent with this, where immunity against 
other viruses (including HBV, HCV, HIV and JEV) has been described in 
exposed seronegative individuals, T-cells were noted to be more likely 
to target non-structural proteins, such as polymerase, than in those 
with seropositive infection23–27.
SARS-CoV-2 T-cells in seronegative HCW
We compared T-cell reactivity in intensively monitored infected 
or SN-HCW, matched for exposure risk and demographic factors 
(COVIDsortium, Extended Data Table 1, Fig. 1a). Additional control 
cohorts comprised healthy adults sampled in London, UK or Sin-
gapore prior to SARS-CoV-2 circulation in humans (pre-pandemic 
cohort; Fig. 1a). SN-HCW were defined by negative weekly diag-
nostic tests (baseline-wk16, SARS-CoV-2 PCR, nasopharyngeal 
swab; anti-Spike-1 IgG and anti-nucleoprotein [NP] IgG/IgM 
seroassays28, Fig. 1b-d). Having previously reported a range of nAb 
titres at wk16 in laboratory-confirmed infection, we examined 
nAb in SN-HCW. Two HCW with nAb titres just above the thresh-
old were excluded from further analyses; the remaining SN-HCW 
were negative by pseudotype assay (Fig. 1e), with a subset also 
confirmed negative at three time points for authentic virus neu-
tralisation (Extended Data Fig. 1a). SN-HCW could have become 
PCR negative by recruitment, however, non-seroconverters after 
PCR positivity were rare (2.6% of PCR+ HCW negative by all 3 
seroassays16) and antibody responses are unlikely to have waned 
before recruitment28. Furthermore, SN-HCW lacked detectable 
SARS-CoV-2 spike-specific memory B-cells, which we have shown 
persist after waning of nAb29 (Extended Data Fig. 1b, below detec-
tion threshold). Thus, SN-HCW represented a cohort of intensely 
monitored HCW who resisted classical laboratory-confirmed 
infection.
We quantified SARS-CoV-2-specific memory T-cells by ELISpot 
using unbiased stimulation with overlapping peptides covering 
structural proteins and the less well-studied non-structural proteins 
of the RTC (Fig. 1f). As previously described, when using sensitive 
assays5–7,9,17,18 (e.g. 400,000 PBMC/well IFNγ-ELISpot used here8,16), 
some SARS-CoV-2-reactive T-cells were detectable in pre-pandemic 
samples; however, their multispecificity was significantly lower than 
in the wk16 laboratory-confirmed infection group (Fig. 1g-h; structural 
responses at wk16 previously reported16). By contrast, SN-HCW had 
SARS-CoV-2-specific T-cells comparable in breadth to infected HCW at 
wk16 and significantly more multispecific than pre-pandemic samples 
(Fig. 1g-h). SN-HCW targeted more protein pools and had a ~5-fold 
higher cumulative magnitude of responses, than pre-pandemics, 
with an overall strength equivalent to the infected cohort at wk16 
(Fig. 1i-j).
T-cells from pre-pandemic samples tended not to target both halves 
of NP (NP1 & NP2 subpools), whereas around 50% of SN-HCW and 
laboratory-confirmed infection group did, confirming our earlier 
suggestion8 that this serves as a simple proxy-measure of a multispe-
cific response (Extended Data Fig. 1c-e). Taken together, we found 
a higher magnitude and breadth of SARS-CoV-2-specific T-cells in 
repeatedly PCR and antibody negative HCW than in a pre-pandemic 
cohort.
RTC-specific T-cells and IFI27 in SN-HCW
We next asked whether T-cell memory differs in SN-HCW versus HCW 
with laboratory-confirmed infection. Anti-viral T-cells recognising 
Influenza A (flu), Epstein-Barr virus (EBV) and cytomegalovirus (CMV) 
(FEC) were equivalent between the three cohorts (Extended Data 
Fig. 2a). However, the relative immunodominance of T-cells against 
SARS-CoV-2 structural versus RTC proteins differed between groups. 
The laboratory-confirmed infection group had more responses to struc-
tural proteins (Spike, Membrane, NP, and ORF3a) than to RTC (NSP7, 
NSP12, NSP13) (Fig. 2a-b). Memory T-cells against structural proteins 
tended to positively correlate with viral load, whereas RTC responses 
did not show this association (Extended Data Fig. 2b). By contrast, 
SN-HCW targeted both structural and RTC regions, with significantly 
more RTC-specific T-cells than either the infected or pre-pandemic 
groups (Fig.2a, Extended Data Fig. 2c-d). Pre-pandemic samples had 
a ratio of RTC to structural responses that did not differ significantly 
from that in SN-HCW (Fig.2b), pointing to a possible influence of 
pre-existing responses on the pool of T-cells expanding in SN-HCW. 
A further small group (10%) of HCW had PCR-confirmed infection but 
lacked detectable nAb at wk16, some of whom also lacked binding 
antibodies; interestingly this sub-group was similarly enriched for 
RTC-reactive T-cells (Extended Data Fig. 2e-f). Taken together, this sug-
gests that the structural proteins, abundantly produced during active 
infection, are dominant T-cell targets after mild infection, whereas 
T-cells in SN-HCW preferentially focus on the RTC.
To confirm the T-cell identity of ELISpot responses in SN-HCW at 
wk16 we expanded them with RTC peptides and detected both CD4+ 
and CD8+ SARS-CoV-2-specific T-cells dividing (CTV dilution) and 
producing IFNγ (Extended Data Fig. 3a; Extended Data Table 2). Their 
post-expansion frequencies tended to be lower than control flu/EBV/
CMV-specific responses in the same donors but proportional to their 
differing ex vivo frequencies, indicating comparable proliferative 
potential (Extended Data Fig. 3b). In vitro expanded RTC-specific T-cells 
in SN-HCW were also highly functional, producing multiple cytokines 
in tandem (Extended Data Fig. 3c-d). Most of the SARS-CoV-2-specific 
T-cells expanded from SN-HCW were CD4+, however, CD8+ T-cells were 
also detectable in the majority of individuals (Extended Data Fig. 3e).
Our data raised the possibility that SARS-CoV-2 infection in HCW 
represents a spectrum, with some SN-HCW expanding T-cells as a result 
of sub-clinical infection not detectable by PCR or antibody serocon-
version. To test this postulate, we measured the interferon-inducible 
transcript IFI27 in blood, which we recently showed detects SARS-CoV-2 
infection at, or one week before, PCR positivity (specificity 0.95 and sen-
sitivity 0.8414). Of the 25% of SN-HCW with the strongest post-exposure 
RTC-specific T-cell responses (Extended Data Fig. 4a), 40% (i.e. 10% of 
SN-HCW group) already had IFI27 levels at recruitment that were above 
the threshold set on a cohort of unexposed pre-pandemic samples, 
although their levels tended to be lower than in laboratory-confirmed 
infection (Fig. 2c). To further estimate the frequency of abortive infec-
tions we tested a larger cohort of 99 unselected SN-HCW baseline sam-
ples, finding a comparable proportion (9.1%) had IFI27 induction above 
the pre-pandemic threshold (Fig. 2c). IFI27 signal peaked above the 
pre-pandemic threshold in 93.3% of those with strong RTC-specific 
T-cells over wk0-5, but in none with weak or undetectable RTC-specific 
T-cells (Fig. 2c). IFI27 levels showed a cumulative increase, peaking 
at 3-5 weeks post-UK lockdown (Fig. 2d, by which time all first wave 
laboratory-confirmed infections had occurred Fig. 1b). By contrast IFI27 
was unchanged over wk0-5 in SN-HCW with weak or absent RTC-specific 
responses, resulting in lower IFI27 slope and variance (Fig. 2d, Extended 
Data Fig. 4b-c). Peak IFI27 level correlated with NSP7 T-cells at wk16, with 
the latter correlating more strongly with NSP12 and other RTC-specific 
than structural responses. Neither IFI27 or T-cell specificity correlated 
with age, sex, or other demographic factors, such as exposure type, 
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In summary, during a period of high transmission at the start of the 
first UK pandemic wave, a low-level systemic interferon response indica-
tive of virus exposure was detectable selectively in individuals who had 
the strongest SARS-CoV-2-specific T-cells post-exposure, despite them 
lacking PCR or antibody confirmation of infection. Extrapolating from 
our previous data showing that IFI27 is induced at the time of incident 
infection and correlates with viral load14, this is consistent with low-level 
infection among SN-HCW with stronger RTC-specific T-cell responses.
Targeting of conserved RNA-polymerase
A transient/abortive infection not detectable by PCR or seroconver-
sion could conceivably result from a lower viral inoculum and/or from 
a more efficient innate and/or adaptive immune response. The latter 
would be favoured by pre-existing memory T-cells with the potential 
to expand rapidly upon cross-recognition of early viral products of 
SARS-CoV-2 replication. Early T-cell proliferation and T-cell receptor 
clonal expansion, even prior to detectable virus, has been observed 
during mild SARS-CoV-2 infection17,30 and expansion of virus-specific 
T-cells predates antibody induction after mRNA vaccination2,31. Hav-
ing found the SN-HCW group to be enriched for SARS-CoV-2-specific 
T-cells, particularly against RTC, we investigated the possibility that 
some of these represented expansions of pre-existing cross-reactive 
responses.
Likely candidates for the source of pre-existing T-cells that 
cross-recognise SARS-CoV-2 are previous infections with closely 
related human endemic common cold coronaviruses (α-HCoV 229E, 
NL63, and β-HCoV HKU1, OC43). We bioinformatically determined the 
sequence homology of all possible SARS-CoV-2-derived 15mer pep-
tides to a curated set of HCoV sequences (Supplementary Table 1). RTC 
proteins, expressed at the first stage of the SARS-CoV-2 life cycle13, had 
15mer sequences of high homology to HCoV (Fig. 3a)32,33. In particular, 
NSP7, NSP12, and NSP13-derived 15mers had 6.3, 29.9 and 31.0% higher 
average sequence homology to the four HCoV species compared to 
structural protein-derived 15mers (all p<0.001, Fig. 3b). NSP12 being 
the largest of these proteins, represented the region with the most 
homology overall amongst human-infecting Coronaviridae. We further 
assessed diversity across global circulating SARS-CoV-2 sequences 
(13,785 representative sub-sample of 611,893 sequences, GISAID, 27th 
July 2021; Extended Data Fig. 5a) using Nei’s genetic diversity index and 
an estimate of the minimal number of independent mutational events 
(homoplasies) at any nucleotide. By both metrics, RTC proteins NSP12 
and NSP13 were among the most conserved across SARS-CoV-2 clades 
(Fig.3c, Extended Data Fig. 5b-d) and were significantly more conserved 
than many structural proteins (Extended Data able 3).
Importantly, the highly conserved RNA-polymerase (NSP12) was 
also the region amongst those tested in pre-pandemic samples that 
was most commonly targeted by T-cells, with the highest average mag-
nitude and frequency of responders (Fig. 3d). Of note, the same pref-
erential targeting of NSP12 was observed in a geographically distinct 
cohort of pre-pandemic samples from Singapore (Fig. 3d). Pre-existing 
T-cells had the potential to recognise all viral antigens tested, including 
those with less conservation across HCoV, as previously described5,7,17,34. 
Responses against these regions were further enriched in SN-HCW 
(Fig. 3d-e; Mann-Whitney p<0.0001 for all except ORF3a p=0.0006, 
NSP13 p=0.0003), suggesting many sources of pre-existing and de novo 
responses contribute to T-cell memory in exposed seronegative indi-
viduals. Despite potential demographic confounders between cohorts 
(Extended Data Table 1), as with pre-pandemics samples, SN-HCW pref-
erentially targeted NSP12 (Fig. 3e). Therefore, the viral protein most 
commonly targeted by pre-existing T-cells is also the largest conserved 
region between coronaviridae, suggesting exposure to HCoV is one 
likely source of cross-reactive T-cells.
To further explore the potential for cross-reactivity due to prior 
infection with seasonal HCoV, we mapped novel and previously 
described6,8,18,35 RTC-specific CD4+ and CD8+ T-cell epitopes in 
SN-HCW, revealing high sequence conservation with HCoV (Extended 
Data Table 4; Extended Data Fig. 6a-b). We identified cross-reactivity 
against the HLA-A*02:01 restricted epitope in NSP7. A subset of T-cells 
co-stained with MHC class I pentamers loaded with SARS-CoV-2 and 
HKU1 sequence peptide ex vivo, and bound SARS-CoV-2 peptide-loaded 
pentamer after 10-day expansion with either peptide (Extended Data 
Fig. 6c). T-cells from 3/5 HLA-A*02:01+ SN-HCW tested had stronger 
responses to the HKU1 sequence than to other seasonal HCoV or 
SARS-CoV-2 (Extended Data Fig. 6d-e). This suggested prior HKU1 infec-
tion primed these NSP7 responses that are able to cross-recognise 
the SARS-CoV-2 sequence, albeit with reduced efficiency. HLA-B*35+ 
SN-HCW also showed variable cross-recognition of seasonal HCoV 
variant sequences of an NSP12 epitope (Extended Data Fig. 6f).
An alternative explanation for expanded T-cells with cross-reactive 
potential in SN-HCW is an infection with a seasonal coronavirus dur-
ing the first wave of SARS-CoV-2 infections in London. As expected, 
all HCW had detectable anti-spike IgG against the 4 endemic HCoV 
and, as previously described36, spike-specific antibodies against 
β-coronavirus OC43 were boosted in those with PCR detectable 
infection and SARS-CoV-2-specific seroconversion (Extended Data 
Fig. 7). However, there was no difference in endemic HCoV titres in 
HCW who had strong RTC-specific T-cells and raised IFI27 compared 
to those with weak or absent RTC-specific responses (Extended Data 
Fig. 7), making it unlikely that HCoV infection itself accounted for the 
SARS-CoV-2-reactive T-cells we detected in SN-HCW.
In summary, RTC regions like polymerase, expressed in the first 
stage of the viral life cycle, are highly conserved among HCoV and 
are preferentially targeted by T-cells in pre-pandemic and SN-HCW 
samples. A subset of T-cells from donors able to abort infection could 
cross-recognise SARS-CoV-2 and HCoV sequences at individual RTC 
epitopes, pointing to prior infection with HCoV as one source of 
pre-existing cross-reactive T-cells.
Polymerase T-cells in abortive infection
To examine whether pre-existing cross-reactive and/or rapidly gener-
ated de novo RTC-specific T-cells expand in vivo, we obtained paired 
PBMC samples pre- and post-SARS-CoV-2 exposure. Medical students 
and laboratory staff (Contact Cohort, n = 23) sampled prior to the 
COVID-19 pandemic (winter 2018-2019), were re-sampled after close 
contact with infected cases, with or without IgG seroconversion +/- PCR 
positivity (Contact Cohort, Extended Data Table 5). Parallel analysis 
of pre- and post-exposure/infection PBMC demonstrated expansion 
of RTC over structural responses in the close-contact seronegative 
group (Fig. 4a). By contrast, the group with serological confirmation 
of infection showed the expected in vivo expansion of pre-existing 
structural SARS-CoV-2-reactive T-cells, with no significant increase 
in RTC-specific T-cells (Fig. 4a; Extended Data Fig. 8a). We observed 
in vivo expansion of pre-existing NSP12 responses in 4/5 individuals 
who remained seronegative after exposure to SARS-CoV-2, resulting in 
a significant increase in NSP12 but not control Flu/EBV/CMV responses 
(Extended Data Fig. 8b-c). 4/5 remaining seronegative close contacts 
had newly detected, presumed de novo, low-level responses after expo-
sure (Extended Data Fig. 8c).
We then reverted to the SN-HCW group, where small volume PBMC 
collections were available from the time of recruitment, allowing 
targeted analysis of baseline T-cells in those with the strongest RTC 
responses at wk16. NSP12-specific T-cells were already detectable at 
baseline in 79% of those SN-HCW with the strongest NSP12 responses 
post-exposure (Fig. 4b). NSP12 responses expanded in vivo on aver-
age 8.4-fold between recruitment and wk16, with no corresponding 
change in Flu/EBV/CMV responses (Fig. 4c, Extended Data Fig. 8d). We 
confirmed the expansion at wk16 of pre-existing RTC-specific T-cells at 

























(Fig. 4c, Extended Data Fig. 8g). In addition, many T-cells were newly 
detected post-exposure (Extended Data Fig. 8g), reflecting either 
de novo priming or expansion of responses previously below the limit 
of assay detection (example of expanded response undetectable by 
ex vivo ELISpot, Extended Data Fig. 8h). All HCW with newly detected 
or expanding/contracting NSP12-specific T-cells had both NP1 and 
NP2-reactive T-cells after exposure (Extended Data Fig. 8i), whereas 
only 2/5 with no change in NSP12 had these specificities, suggesting 
they may not have had the same level of SARS-CoV-2 exposure. The 
fold-change in NSP12 between recruitment and wk16 follow-up cor-
related with the total SARS-CoV-2 response, supporting its utility to 
identify seronegative individuals expanding T-cell immunity after 
exposure (Extended Data Fig. 8j).
Finally, we examined whether there was a preferential enrich-
ment of RTC-specific responses in SN-HCW compared to the 
laboratory-confirmed infected HCW at wk16. Strikingly, the 
RNA-polymerase NSP12 and its cofactor NSP7 were the only proteins 
inducing higher magnitude T-cell responses in seronegative individuals 
in whom detectable infection was not established compared to those 
with overt infection (Fig. 4d). T-cells in SN-HCW targeted a larger num-
ber of regions of NSP12 (subpools of ~40 overlapping 15mers, Fig. 1g) 
than those in pre-pandemic or seropositive cohorts (Extended Data 
Fig. 8k). T-cells targeting several regions of NSP12 and other RTC pools 
were enriched in SN-HCW compared to laboratory-confirmed infection 
(Fig. 4d, lower panel). To examine whether the reduced frequency 
of NSP12-specific T-cells in the 16wk memory response of those with 
laboratory-confirmed infection was reflective of their repertoire at the 
time of encountering SARS-CoV-2, we obtained baseline PBMC from 
a subset sampled prior to PCR positivity or >4wks before seroconver-
sion. NSP12-specific T-cells were already significantly lower at baseline 
in those that went on to develop laboratory-confirmed infection than 
in SN-HCW (Fig. 4e, Extended Data Fig. 8l-m), supporting a potential 
role in protection from PCR-detectable infection and seroconversion.
Conclusions
We provide T-cell and innate transcript evidence for abortive, seron-
egative SARS-CoV-2 infection. Longitudinal samples from SN-HCW and 
an additional cohort, showed RTC (particularly polymerase)-specific 
T-cells were enriched before exposure, expanded in vivo, and prefer-
entially accumulated in those in whom SARS-CoV-2 failed to establish 
infection, compared to those with overt infection.
The differential biasing of T-cells towards early expressed 
non-structural SARS-CoV-2 proteins in HCW not seroconverting may 
reflect repetitive occupational exposure to very low viral inocula, 
reported to drive the induction of non-structural T-cells in HIV, SIV 
and HBV26,37,38. Such repetitive exposure would be congruent with the 
observed protracted induction of the innate signal IFI27 and the devel-
opment of de novo T-cells in some SN-HCW.
However, we also documented expansion of pre-existing T-cells, with 
responses capable of cross-recognising epitope variants between sea-
sonal HCoV and SARS-CoV-2. Cross-reactive SARS-CoV-2-specifc CD8+ 
T-cells directed against epitopes highly conserved among HCoV are now 
well-described, with pre-existing T-cells frequently targeting essential 
viral proteins with low scope for tolerating mutational variation, such 
as those in ORF1ab6,18,32. The abundant SARS-CoV-2-specific CD4+ T-cells 
may also contribute to protection in SN-HCW by antibody-independent 
mechanisms, such as antiviral cytokines and chemokines production. 
HCW have higher frequencies of HCoV-reactive T-cells than the general 
public19 and recent HCoV infection is associated with reduced risk of 
severe COVID-19 infection39, likely partly attributable to cross-reactive 
neutralising antibodies;40,41 however, pre-existing T-cells have also been 
implicated15,42. The early induction of T-cells, before detectable antibod-
ies in mild infection30 and concurrent with mRNA vaccination efficacy, 
support a role for pre-existing cross-reactive memory T-cells2,31.
Pre-existing RTC-specific T-cells, at higher frequency than 
naïve T-cells and poised for immediate re-activation on antigen 
cross-recognition, would be expected to favour early control, explain-
ing their enrichment after abortive compared to classical infection. 
However, the relative contribution of viral inoculum and cross-reactive 
T-cells needs to be further dissected in human challenge experiments 
and animal models. A caveat of this work is that we only analysed 
peripheral immunity; it is plausible that mucosal-sequestered anti-
bodies43 played a role in our seronegative cohort. It also remains pos-
sible that innate immunity mediates control in abortive infections, 
with RTC-biased T-cell responses being generated as a biomarker of 
low-grade infection. Interferon-independent induction of RIG-I has 
been proposed to abort SARS-CoV-2 infection by restraining the viral 
lifecycle prior to sgRNA production;13 this would favour the presenta-
tion of epitopes from ORF1ab, released into the cytoplasm in the first 
stage of the viral life cycle12, whilst blocking production of structural 
proteins from pgRNA. This raises the possibility that some SARS-CoV-2 
infected cells could be recognised and removed by ORF1ab-reactive 
T-cells without widespread production of structural proteins and 
mature virion formation.
We have described induction of innate and cellular immunity with-
out seroconversion, highlighting a subset of individuals where risk of 
SARS-CoV-2 reinfection and immunogenicity of vaccines should be 
specifically assessed. The HCW we studied were exposed to Wuhan 
Hu-1 and had partial protection from PPE; it remains to be seen whether 
abortive infections can occur upon exposure to more infectious vari-
ants of concern, or in the presence of vaccine-induced immunity. How-
ever, clearance without seroconversion points to T-cells which may 
be particularly effective vaccine targets. Cross-protection between 
coronaviruses is proportional to their sequence homology in mice44, 
making the highly conserved NSP12 region studied here, as well as less 
studied NSP3/14/16, top candidates for heterologous immunity. Our 
data highlight the presence of pre-existing T-cells in a proportion of 
donors that are able to expand in vivo and target a highly conserved 
region of SARS-CoV-2 and other Coronaviridae. Boosting of such T-cells 
may offer durable pan-Coronaviridae reactivity against endemic and 
emerging viruses, arguing for their inclusion and assessment, as an 
adjunct to spike-specific antibodies, in next-generation vaccines.
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Fig. 1 | SARS-CoV-2-specific T-cells in seronegative HCW. a, Design of HCW 
and pre-pandemic cohorts. b, Cycle threshold values for E gene PCR in SN-HCW 
and laboratory-confirmed infection (undetectable at 40 cycles assigned 41).  
c, Anti-Spike S1 and d, anti-NP antibody titres in SN-HCW (baseline to wk16; 
n=58; dotted lines at assay positivity cut-off and at average peak [AvPos] 
response in laboratory-confirmed infection). e, Pseudovirus neutralisation at 
wk16. Crossed circles excluded from SN-HCW group (IC50 >50). f, SARS-CoV-2 
proteome highlighting RTC and structural regions assayed for T-cell responses 
(peptide subpools identified by numbered boxes) and the number of 
overlapping 15mer peptides (or mapped epitope peptides [MEP] for spike) in 
brackets below. g, Viral proteins recognised by individuals coloured by 
specificity and h, number of viral proteins targeted by group. i, Magnitude of 
T-cell response coloured by viral protein and j, cumulative magnitude of T-cell 
response by group. Red bar, geomean. g-j, IFNγ-ELISpot. e,h, Red bar, median. 
h,j, Kruskal-Wallis with Dunn’s correction. M, membrane; NP, nucleoprotein; 
RTC, replication-transcription complex; SFC, spot forming cells.  
b-e,g-j, COVIDsortium HCW cohort.

























IEW Fig. 2 | RTC-specific T-cell and IFI27 signature in SN-HCW. a, Magnitude of T-cell response to structural regions and RTC. b, Ratio of T-cell response to  
RTC versus structural regions. Percentage of cohort with a ratio above 1 
(RTC>Structural) shown below. c, IFI27 transcript signal by RT-PCR in 
unexposed pre-pandemic samples (n=59), baseline samples in HCW that 
remained PCR- and seronegative throughout follow-up (n=99), SN-HCW with 
weak (n=5, <50 SFC/106 PBMC, Extended Data Fig. 4a) or strong (n=15, >50 
SFC/106 PBMC) RTC-specific T-cells (baseline [BL] and peak signal [wk0-5]), and 
HCW at the time of PCR positivity (PCR+). d, longitudinal IFI27 signal in 
SN-HCW with weak or strong RTC-specific T-cell responses (n as in c).  
c,d, 2 standard deviations (SD) either side of the pre-pandemic cohort mean 
highlighted by grey area and percentage with raised IFI27 above mean+2SD 
indicated below. a-b, IFNγ-ELISpot. a-b, Red bar, geomean. c-d, Red bar, 
median. a-d, Kruskal-Wallis ANOVA with Dunn’s correction. c, Mann-Whitney 
paired t-test. a-b, wk16. a-d, COVIDsortium HCW cohort.

























Fig. 3 | Cross-reactive T-cells targeting conserved RNA-polymerase.  
a, Heatmap, sequence homology of SARS-CoV-2-derived peptide sequences to 
HCoV sequences. Columns, 15mer SARS-CoV-2-derived peptides. Rows, HCoV 
genome records. Cells are coloured by the level of homology of the 15mer to a 
particular HCoV proteome. Heatmap cells with no fill indicate sequence 
homology <40% was observed. b, Average sequence homology of 15mers 
covering SARS-CoV-2 proteins, or regions (pink, structural [S, M, NP, ORF3a]; 
black, RTC [NSP7, NSP12, NSP13]), to HCoV sequences. Viral proteins not 
assayed for T-cell responses are shown in grey. c, Nucleotide diversity along the 
SARS-CoV-2 genome estimated with Nei’s genetic diversity index, across each 
viral protein for all SARS-CoV-2 clades (subsampling Extended Data Fig. 5a).  
d, Magnitude of T-cell responses to individual SARS-CoV-2 proteins in 
unexposed pre-pandemic samples and e, SN-HCW at wk16. Frequency of 
responders shown as doughnuts above. d-e, IFNγ-ELISpot, bar at geomean.  
nd, not done. d,e Kruskal-Wallis with Dunn’s correction. d-e, COVIDsortium 
HCW cohort.


























Fig. 4 | In vivo expansion of polymerase-specific T-cells in abortive 
infection. a, Magnitude of T-cell response in seronegative close contacts of 
cases (green), or in seropositive infected individuals (orange) to RTC, 
structural proteins, summed total, and Flu, EBV, CMV (FEC) peptide pool (grey 
seronegative/seropositive combined), before and after exposure/infection. 
Bar, mean + SEM. b, Change in magnitude of NSP12 T-cell response between 
recruitment and post-exposure in SN-HCW (sub-group with top 19 RTC 
responses at wk16, Extended Data Fig. 4a). Expanded, >2-fold change.  
c, Magnitude of paired pre- and post-exposure T-cell responses to individual 
9-15mer peptides (individual responses Extended Data Fig. 8g) from RTC or 
control FEC pool in SN-HCW (wk16-26, 11 responses from 9 SN-HCW).  
d, Magnitude of T-cell response to individual SARS-CoV-2 proteins (upper 
panel) and to subpools (~40 overlapping peptides; lower panel) within RTC at 
wk16 in laboratory-confirmed infected HCW or SN-HCW. e, Pre-existing 
NSP12-specific T-cell responses in baseline samples from SN-HCW and 
laboratory-confirmed infection group (PCR+ after baseline or seroconversion 
at least 4 weeks post-recruitment). Doughnut plot above shows frequency.  
a-e, IFNγ-ELISpot. c, d-e Red line/bars, geomean. a,c Wilcoxon test.  
d,e, Mann-Whitney test and Fisher’s exact test. a, Contact cohort, Extended 
Data Table 5. b-e, COVIDsortium HCW cohort, Extended Data Table 1).


























COVIDsortium Healthcare Worker Participants
The COVIDsortium bioresource was approved by the ethical committee 
of UK National Research Ethics Service (20/SC/0149) and registered on 
ClinicalTrials.gov (NCT04318314). Full study details of the bioresource 
(participant screening, study design, sample collection, and sample 
processing) have been previously described16,45.
In this cohort and London as a whole infections peaked for the first 
pandemic wave of infections during the first week of lockdown (March 
23rd 2020)46, and we observed approximately synchronous exposure 
coincident with recruitment, we therefore used this as the benchmark 
for assessing exposure generated immunity. Across the main study 
cohort, 48 participants had positive RT-PCR results with 157 (21.5%) 
seropositive participants. 79% of positive PCR tests were within the 
first 2 weeks of follow-up and no HCW tested PCR+ after week 5 of 
follow-up (Fig. 1b)14,46, with seroconversion within the first 3 weeks of 
follow-up for most28. Infections were asymptomatic or mild with only 
two hospital admissions (none requiring intensive care admission). The 
cross-sectional case controlled sub-study (n=129) collected samples 
at 16-18 weeks after the first UK lockdown (Fig. 1a). Power calculations 
were performed prior to week 16 sub-study sampling to determine the 
sample size needed to test the hypothesis that HCW with pre-existing 
T-cell responses are enriched in exposed seronegative group at a 
range of incidence of infection, assuming 50% of the total cohort had 
pre-existing T-cell responses. Sample sizes of 18-64 per group were 
estimated. An age, sex and ethnicity matched nested sub-study was 
designed within the larger (n=731) parent study and 129 attended for 
16-week sampling including high volume PBMC isolation.
Laboratory-confirmed infection was determined by weekly naso-
pharyngeal RNA stabilizing swabs and reverse transcriptase polymerase 
chain reaction (RT-PCR; Roche cobas SARS-CoV-2 test, Envelope [E] 
gene) and antibody assay positivity (Spike protein 1 IgG Ab assay, EURO-
IMMUN) and anti-nucleocapsid total antibody assay (ROCHE) described 
in detail below. The seronegative health care worker group were 
matched for demographics and exposure to the laboratory-confirmed 
infected group and was defined by negativity by these 3 tests at all 16 
time points as well as negative for neutralising antibodies at week 16 
and at selected prior time points as indicated.
The cohort of medical students and laboratory staff was approved by 
UCL Ethics (Project ID Number:13545/001) and pre-pandemic healthy 
donor samples were collected and cryopreserved before August 2019 
under ethics numbers 11/LO/0421. All subjects gave written informed 
consent and the study conformed to the principles of the Helsinki 
Declaration.
Isolation of PBMC and Serum
Peripheral blood mononuclear cells (PBMC) were isolated from heparin-
ized blood samples using Pancoll (Pan Biotech) or Histopaque®-1077 
Hybri-MaxTM (Sigma-Aldrich) density gradient centrifugation in Sep-
Mate tubes (StemCell) according to the manufacturer’s specifications. 
Isolated PBMC were cryopreserved in fetal calf serum (FCS) containing 
10% DMSO and stored in liquid nitrogen.
Whole blood samples were collected in SST vacutainers (VACUETTE) 
with inert polymer gel for serum separation and clot activator coating. 
After centrifugation at 1000 X g for 10 min at room temperature (RT), 
serum layer was aliquoted and stored at -80 °C. All T-cell assays reported 
here were performed on cryopreserved PBMC.
Weekly SARS-CoV-2 S1 and NP Serology
Weekly Euroimmun anti-SARS-CoV-2 enzyme-linked immunosorbent 
assay (ELISA; anti-SARS-CoV-2 S1 antigen IgG and the Roche Elecsys 
anti-SARS-CoV-2 electrochemiluminescence immunoassay (ECLIA; 
anti-SARS-CoV-2 nucleoprotein IgG/IgM) commercial assays were per-
formed by Public Health England as previously described16. S1 ELISA: 
A ratio of ≥ 1.1 was deemed positive. A ratio of 11 was taken to be the 
upper threshold as the assay saturates beyond this point. NP ECLIA: 
Anti-NP results are expressed as a cut-off index (COI) value based on 
the electrochemiluminescence signal of a 2-point calibration, with 
results COI ≥1.0 classified as positive.
Neutralization assays – Pseudotype and authentic virus
SARS-CoV-2 pseudotype neutralisation assays were conducted using 
pseudotyped lentiviral particles as previously described16. Briefly, 
serum was heat-inactivated at 56 oC for 30 mins. Serum dilutions in 
DMEM were performed in duplicate with a starting dilution of 1 in 20 
and 7 consecutive 2-fold dilutions to a final dilution of 1/2,560 in a total 
volume of 100 µl. 1 x 105 RLU of SARS-CoV-2 pseudotyped lentiviral 
particles were added to each well (serum dilutions and controls) and 
incubated at 37 °C for 1 hr. 4 x 104 Huh7 cells suspended in 100 µl com-
plete media were added per well and incubated for 72 hr at 37 °C and 
5% CO2. Firefly luciferase activity (luminescence) was measured using 
Steady-Glo® Luciferase Assay System (Promega) and a CLARIOStar 
Plate Reader (BMG Labtech). The curves of relative infection rates (in 
%) versus the serum dilutions (log10 values) against a negative control 
of pooled sera collected prior to 2016 (Sigma) and a positive neutraliser 
were plotted using Prism 9 (GraphPad). A non-linear regression method 
was used to determine the dilution fold that neutralised 50% (IC50).
Authentic SARS-CoV-2 microneutralization assays were carried 
out as previously described47. Briefly, a mixture of serum dilutions in 
DMEM (1 in 20 and 11 consecutive 2-fold dilutions to a final dilution 
of 1/40,960) and 3 x 104 FFU of SARS-CoV-2 virus (Wuhan Hu-1) were 
incubated at 37 °C for 1 hr. After initial incubation, pre-seeded Vero E6 
cells were infected with the serum-virus samples and incubated (37 °C 
and 5% CO2) for 72 hr. Cells were then fixed with 100 µl 3.7% (vol/vol) 
formaldehyde for 1 hr. Cells were washed with PBS and stained with 0.1% 
(wt/vol) crystal violet solution for 10 minutes. After removal of excess 
crystal violet and air drying, the crystal violet stain was re-solubilized 
with 100 µl 1% (wt/vol) sodium dodecyl sulfate solution. Absorbance 
readings were taken at 570 nm using a CLARIOStar Plate Reader (BMG 
Labtech). Absorbance readings for each well were standardised against 
technical positive (virus control) and negative (cells only) controls on 
each plate to determine a percentage neutralisation value. A non-linear 
regression (curve fit) method was used to determine the dilution fold 
that neutralised 50% (IC50) using Prism 9 (GraphPad). SARS-CoV-2 is 
classified as a hazard group 3 pathogen and therefore all authentic 
SARS-CoV-2 propagation and microneutralization assays were per-
formed in a containment level 3 facility.
Spike ELISA
Seropositivity against SARS-CoV-2 spike was determined for medical 
student and laboratory staff cohort between July 2020 and Jan 2021 
(Extended Data Table 5) by enzyme-linked immunosorbent assay, 
as validated and described previously40,48,49. Briefly, 9 columns of 
96-half-well MaxiSorp plates (Thermo Fisher Scientific) were coated 
overnight at 4 °C with purified S1 protein in PBS (3 µg/ml per well 
in 25 µl), the remaining 3 columns were coated with goat anti-human 
F(ab)’2 (1:1,000) to generate in internal standard curve. The next day, 
plates were washed with PBS-T (0.05% Tween in PBS) and blocked for 
1 hr at RT with assay buffer (5% milk powder PBS-T). Sera were diluted 
in blocking buffer (1:50). 25 µl of serum was then added to S1 coated 
wells in duplicate and incubated for 2 hr at RT. Serial dilutions of known 
concentrations of IgG were added to the F(ab)’2 IgG-coated wells in 
triplicate (Sigma Aldrich). Following incubation for 2 hr at RT, plates 
were washed with PBS-T and 25 µl alkaline phosphatase-conjugated 
goat anti-human IgG ( Jackson ImmunoResearch) at a 1:1000 dilution 
in assay buffer added to each well and incubated for 1 hr RT. Plates 
were then washed with PBS-T, and 25 µl of alkaline phosphatase sub-
strate (Sigma Aldrich) added. ODs were measured using a MultiskanFC 


























titers interpolated from the IgG standard curve using 4PL regression 
curve-fitting on GraphPad Prism 8.
HCoV spike Meso scale discovery immunoassay (MSD)
A multiplexed MSD immunoassay to measure anti-HCoV spike IgG 
antibodies was performed as previously described50. Plates were coated 
with 200-400 µg/ml spike protein (trimers in pre-fusion form) from the 
endemic human coronaviruses HKU1, OC43, 229E and NL63. Antibody 
concentration is presented in arbitrary units (AU) interpolated from the 
ECL signal of the internal standard sample using a 4-parameter logistic 
curve fit. Serum samples taken at wk8, the peak time point for Spike S1 
IgG after PCR+ SARS-CoV-2 infection, were assayed for HCoV antibodies.
SARS-CoV-2 spike-specific memory B-cell staining
Multiparameter flow cytometry was used for ex vivo identification of 
spike-specific memory B cells staining as previously described29. Bioti-
nylated tetrameric spike (1 µg) was fluorochrome linked by incubating 
with streptavidin conjugated APC (Prozyme) and PE (Prozyme) for 30 mins 
in the dark on ice. PBMC were thawed and incubated with Live/Dead 
fixable dead cell stain (UV, ThermoFisher Scientific) and saturating 
concentrations of phenotyping mAbs diluted in 50% 1 x PBS 50% Bril-
liant Violet Buffer (BD Biosciences): CD3 Bv510 (Biolegend, clone 
OKT3, 1:200), CD11c FITC (BD Biosciences, clone B-ly6, 1:100), CD14 
Bv510 (Biolegend, clone M5E2, 1:200), CD19 Bv786 (BD Bioscience, 
clone HIB19, 1:50), CD20 AlexFluor700 (BD Biosciences 2H7, 1:100), 
CD21 Bv711 (BD Biosciences, clone B-ly4, 1:100), CD27 BUV395 (BD Bio-
sciences, clone L128, 1:100), CD38 Pe-CF594 (BD Biosciences, clone HIT2, 
1:200), IgD Pe-Cy7 (BD Biosciences, clone IA6-2, 1:100). For identifica-
tion of SARS-CoV-2 antigen specific B cells 1 µg per 500 µl of stain each 
of tetrameric Spike-APC and Spike-PE were added to cells. Cells were 
incubated in the staining solution for 30 mins RT, washed with PBS, and 
subsequently fixed with FoxP3 Buffer Set (BD Biosciences) according 
to the manufacturer’s instructions. All samples were acquired on a BD 
Fortessa-X20 flow cytometer. Data were analysed by FlowJo version 10.7 
(TreeStar). Example gating and positivity cut-off have been previously 
reported29. The magnitude of the SARS-CoV-2 spike-specific memory B 
cell population is expressed as a percentage of memory B cells (gated 
as: lymphocytes, singlets, Live, CD3-CD14-CD19+, CD20+, excluding: 
CD38hi, IgD+ and CD27+CD21-) binding both PE- and APC- labelled spike.
SARS-CoV-2 peptides
Full lists of the peptides contained in pools of overlapping peptides 
covering structural16 and RTC proteins8 have been previously described 
(15mer peptides overlapping by 10 amino acids, GL Biochem Shanghai 
Ltd, >80% purity). Overlapping peptides of NSP12 are listed in Supple-
mentary Table 3. For IFNγ-ELISpot assays SARS-CoV sequence peptides 
were used (96.5% sequence homology with Wuhan SARS-CoV-2 consen-
sus sequence, 34/931 amino acids differ, Supplementary Table 3). For 
epitope mapping SARS-CoV-2 sequence peptides were used for NSP12-2 
and NSP12-5 (GL Biochem Shanghai Ltd, >80% purity).
To limit competition for in vitro for peptide presentation we limit 
stimulations to a maximum of 55 peptides and have, therefore, divided 
large proteins such as NP into subpools: NP (NP1, NP2, 41 peptides 
each), M (43 peptides), ORF3a (53 peptides), NSP7 (15), NSP12 (36-
37 per pool NSP12-1 to NSP12-5) and NSP13 (39-40 peptides per pool 
NSP13-1 to NSP13-3). In addition 15mer peptides covering the predicted 
SARS-CoV-2 spike epitopes8 to give a total of 55 peptides in this pool 
(Spike). Optimal 9mer peptides for CD8+ epitopes were custom syn-
thesised by ThinkPeptides (UK) >70% purity (Supplementary Table 3).
IFNγ-ELISpot Assay
IFNγ-ELISpot Assay was performed as previously described on cryopre-
served PBMC8,16,51. Unless otherwise stated, culture medium for human 
PBMC (R10) was sterile 0.22 µM filtered RPMI medium (Thermo Fisher 
Scientific) supplemented with 10% by volume heat inactivated (1 hr, 
64 °C) FCS (Hyclone) and 1% by volume 100 x penicillin and strepto-
mycin solution (GibcoBRL).
ELISpot plates (Merck-Millipore, MSIP4510) were coated with human 
anti-IFNγ Ab (1-D1K, Mabtech; 10 µg/ml) in PBS overnight at 4 °C. Plates 
were washed 6x with sterile PBS and were blocked with R10 for 2 hr 
at 37 °C with 5% CO2. PBMC were thawed and rested in R10 for 3 hr at 
37 °C with 5% CO2 before being counted to ensure only viable cells were 
included. 400,000 PBMC/well were seeded in R10/well and were stimu-
lated for 16-20 hr with SARS-CoV-2 peptide pools (2 µg/ml per peptide) 
at 37 °C in a humidified atmosphere with 5% CO2. Where insufficient 
T-cells were available NSP12 pools 1,2 and 3 and NSP13 pools 1,2,3 were 
combined into a single well. For baseline measurements NSP12 pools 
1-5 were stimulated in a single well and where insufficient T-cells were 
available a single DMSO well was included. HCW who did not have a 
full complement of stimulations were excluded from analysis of total 
magnitude of breadth of response, hence slightly lower n numbers. 
Internal plate controls were R10 alone (without T-cells) and two DMSO 
wells (negative controls), concanavalin A (ConA, positive control; 
Sigma-Aldrich) and FEC (HLA I-restricted peptides from influenza, 
Epstein-Barr virus, and CMV; 1 µg/ml per peptide). ELISpot plates were 
developed with human biotinylated IFNγ detection antibody (7-B6-
1, Mabtech; 1µg/ml) for 3 hr at RT, followed by incubation with goat 
anti-biotin alkaline phosphatase (Vector Laboratories; 1:1000) for 2 hr 
RT, both diluted in PBS with 0.5% BSA by volume (Sigma-Aldrich), 
and finally with 50 µl/well of sterile filtered BCIP/NBT Phosphatase 
Substrate (ThermoFisher) for 7 min RT. Plates were washed in ddH20 
and left to dry overnight before being read on an AID classic ELISpot 
plate reader (Autoimmun Diagnostika GMBH, Germany).
The average of two DMSO wells was subtracted from all 
peptide-stimulated wells for a given PBMC sample and any response 
that was lower in magnitude than 2 standard deviations of these sample 
specific DMSO control wells was not considered a peptide specific 
response (given value 0). Results were expressed as IFNγ spot forming 
cells (SFC) per 106 PBMC after background subtraction. The geometric 
mean of all DMSO wells was 9.571 SFC per 106 PBMC (3.8 spots). We 
excluded the results if negative control wells had >95 SFC/106 PBMC 
or positive control wells (ConA) were negative. T-cell responses to 
SARS-CoV-2 did not correlate with background spots in DMSO wells 
(e.g. SN-HCW group, Spearman r = -0.068 p = 0.6141).
Antigen-specific T-cell proliferation assay and epitope mapping
Frozen PBMC were thawed and washed twice with sterile PBS. PBMC 
were resuspended in 1 mL R10 culture media (2-10 x 106 PBMC) and 0.5 µL 
of 5 mM stock CellTrace violet (CTV; Thermo Fisher Scientific) was 
added per sample with mixing. PBMC were stained in the dark for 10 mins 
at 37 °C in a humidified atmosphere with 5% CO2. 10-times volume 
of cold R10 was added to stop the staining reaction, and cells were 
incubated for 5 mins on ice. Cells were washed in PBS and incubated 
for 5 mins at 37 °C before being transferred to a new tube and were 
washed again in R10. CTV stained PBMC were plated in 96-well plates 
(2-4 x 105 PBMC in 200 µL R10) and stimulated with peptide pools 
(2 µg/ml per peptide) for 10 days in R10 supplemented with 0.5 µg/ml 
soluble anti-CD28 (Thermo Fisher scientific) and 20 U/ml recombi-
nant human IL2 (Peprotech). CTV-stained and unstained PBMC were 
run to confirm efficiency of staining. 100 µL media was added on day 
1, and 100 µL media removed and replaced with R10 supplemented 
with anti-CD28 and IL2 as above on days 3 and 6. On day 9 PBMC were 
re-stimulated with peptide pools (2 µg/ml per peptide) and brefeldin A 
(10 µg/ml; Sigma-Aldrich). After 16-18 hr re-stimulation PBMC were har-
vested, washed in PBS, and stained for fixable live/dead (Near infrared, 
Thermo Fisher Scientific, 1:1000), washed in PBS, before being fixed 
in Fix/perm buffer (TF staining buffer kit, eBioscience) for 20 mins 
RT. Cells were washed in PBS and incubated in perm buffer (TF stain-
ing buffer kit, diluted 1:10 in ddH2O) for 20 mins RT, washed in PBS 

























anti-human antibodies for intracellular staining: IL-2 PerCp-eFluor710 
(Invitrogen, clone MQ1-17H12, 1:50), TNFα FITC (BD Bioscience, clone 
MAb11, 1:100), CD8α BV785 (Biolegend, clone RPA-T8, 1:200), IFNγ 
BV605 (BD Biosciences, clone B27, 1:100), IFNγ APC (Biolegend, clone 
4S.B3, 1:50), CD3 BUV805 (BD Biosciences, clone UCHT1, 1:200), CD4 
BUV395 (BD Biosciences, clone SK3, 1:200), CD154 (CD40L) Pe-Cy7 
(Biolegend, clone 24-31, 1:50), MIP-1-β PE (BD Biosciences, clone D21-
1351, 1:100). Cells were washed twice in PBS and analysed on a BD LSRII 
flow cytometer. Cytometer voltages were consistent across batches. 
FMOs and unstimulated samples were used to determine gates applied 
across samples. Data were analysed by FlowJo version 10.7 (TreeStar).
Optimisation experiments showed use of rhIL2 increases non-peptide 
specific proliferation of T-cells but is essential for optimal expansion 
of proliferating cytokine producing peptide-specific T-cells. CTV dilu-
tion and staining with anti-human-IFNγ antibodies was used to identify 
antigen-specific T-cells. An unstimulated control well (equivalent DMSO 
to peptide wells added) was included for each PBMC sample and the 
percentage of CTVlo IFNγ+ CD4+ or CD8+ proliferating in unstimu-
lated wells was subtracted as background cytokine release from all 
peptide stimulated wells. The T-cell proliferation assay above was 
used to expand SARS-CoV-2-specific T-cells and a 2-dimension matrix 
(Supplementary Table 2) was employed so that each 15mer peptide 
was represented in 2 pools aiding the identification of individuals 
immunogenic 15mer peptides. T-cell responses were then confirmed 
by repeated expansion with individual 15mers.
Polyfunctionality, defined as the number of cytokines co-produced 
by T-cells after 10-day expansion, was assessed using SPICE (version 6.0) 
and pestle (version 2.0), available at https://niaid.github.io/spice/52. 
Responses <0.1% of CD4+ or CD8+ T-cells were excluded. Boolean gat-
ing was used to identify the percentage of T-cells making the 31 pos-
sible combinations of the following cytokines: IFNγ, TNF, IL-2, CD154, 
MIP-1-β. Pestle was used to background subtract the percentage of 
cytokine producing cells from unstimulated wells ran in parallel and 
to format data for visualisation in SPICE. The proportion of T-cells 
making a specific number of cytokines in combination is presented as 
pie graphs (base mean) and pie arcs represent the proportion making a 
given cytokine. The RTC-specific T-cell polyfunctionality was calculated 
as an average over T-cell responses to NSP7, NSP12 and NSP13 and the 
structural-specific T-cell polyfunctionality is an average of responses 
to Spike, ORF3a, M and NP (Extended Data Fig. 3d).
MHC class I pentamer staining
HLA-A*02-restricted pentamers (Proimmune) of the following specifi-
cities were used: SARS-CoV-2 NSP727-35 (KLWAQCVQL) or HCoV HKU1 
NSP727-35 (KLWQYCSVL; ex vivo stains only). For post-expansion staining: 
antigen-specific T-cells were expanded with cognate 9mer peptide of 
SARS-CoV-2 or HCoV HKUW sequence for 8-10 days as above (2 µg/ml 
per peptide) in R10 supplemented with 0.5 µg/ml soluble anti-CD28 and 
20 U/ml recombinant human IL2; media added on days 1, 3 and 6 prior 
to pentamer staining. For ex vivo staining: PBMC were thawed, washed 
twice in PBS. Pentamers were centrifuged at 13,000 rpm for 10mins 
prior to use. 0.5-2 x 106 PBMC were stained with 1µl pentamers at RT 
for 20mins in 50 µl PBS in a 96-well plate. PBMC were further stained 
with Blue fixable Live/dead (Invitrogen, 1:1000) for 20mins at 4 °C, and 
surface stained with a mixture of saturating concentrations of mAbs 
for 30mins at 4 °C: CD3 BUV805 (BD Biosciences, clone UCHT1, 1:200), 
CD4 BUV395 (BD Biosciences, clone SK3, 1:200), CD56 Pe-Cy7 (BD Bio-
sciences, NCAM16.2, 1:100), CD8α Alexa700 (Biolegend, RPA-78, 1:200), 
post-expansion CD19 Bv786 (BD Biosciences, HIB19, 1:100). PBMC were 
fixed with 1% paraformaldehyde and flow cytometry was performed as 
above using a BD LSRII flow cytometer. Data were analysed by FlowJo 
version 10.7 (TreeStar). During analysis, stringent gating criteria were 
applied (Gating strategy in Extended Data Fig. 6c) with doublet, dead 
cell, CD19+ B cell (post-expansion) and CD56+ NK/NKT exclusion to 
minimize nonspecific binding contamination. HLA-mismatched PBMC 
(non-HLA-A*02) and fluorescence minus one controls for pentamers were 
stained in parallel to assess non-specific binding (Extended Data Fig. 6c).
Coronaviridae family sequence homology analyses
The sequence homology of SARS-CoV-2-derived peptides to HCoV 
sequences was computed as previously described32. Briefly, the 
SARS-CoV-2 proteome (NC_045512.2) was decomposed into 15mer 
peptide sequences overlapping by 14 amino acids. A protein BLAST 
search of each 15mer peptide was then performed against a custom 
sequence database comprising 2531 Coronaviridae sequences32. Homol-
ogy values of each SARS-CoV-2-derived peptide to viral accessions 
with ‘229E’, ‘OC43’, ‘NL63’, or ‘HKU1’ included in the species name and 
that were isolated from human hosts were retained (Supplementary 
Table 1). Additionally, to determine if the conservation of 15mer pep-
tides differed between the SARS-CoV-2 proteins, the average homology 
of peptides within each protein was computed. A permutation test was 
conducted to test if the difference in average homology between the 
two proteins, Δh, was statistically significant. Briefly, the protein mem-
bership of each 15mer peptide was permuted (1000 iterations). The Δh 
of two proteins were then calculated at each iteration, resulting in a final 
null distribution of Δh values. P-values were computed as the number 
of permutations that yielded a Δh at least as extreme as the observed 
Δh of the two proteins. Custom scripts used to perform the homology 
searches, heatmap visualisation and permutation testing are hosted on 
GitHub: https://github.com/cednotsed/tcell_cross_reactivity_covid.git.
For sequence alignments of immunogenic 15mers or at described 
MHC class I-restricted epitopes reference protein sequences for ORF1ab 
(accession numbers: QHD43415.1, NP_828849.2, YP_009047202.1, 
YP_009555238.1, YP_173236.1, YP_003766.2 and NP_073549.1) were 
downloaded from the NCBI database (https://www.ncbi.nlm.nih.gov/
protein/) as previously described8. Sequences were aligned using the 
MUSCLE algorithm with default parameters and percentage identity 
was calculated in Geneious Prime 2020.1.2, www.geneious.com. Align-
ment figures were made in Snapgene 5.1 (GSL Biotech).
SARS-CoV-2 species genome diversity analyses
For genome diversity analysis a complete masked alignment was down-
loaded from the GISAID53,54 EpiCoV database on 26/7/2021 together with 
a GISAID Audacity phylogeny comprising 611,893 accessions (Full list 
and metadata available at:
https://figshare.com/s/049d53f789a8b111b87e). The alignment was 
subsampled to include 800 of each defined NextStrain phylogenetic clade, 
as provided by GISAID metadata. For clades containing less than 800 
accessions all representatives of that clade were included resulting in a 
comprehensive sampling over the global phylogeny of 13,785 accessions 
encompassing the genomic diversity of SARS-CoV-2 to date (Extended 
Data Fig. 5a). Diversity along the genome was assessed using two metrics 
of diversity: the number of recurrent mutational emergences (homopla-
sies) at any position and Nei’s genetic diversity index55. Homoplasy counts 
per locus were computed via application of the HomoplasyFinder screen-
ing pipeline56 against a maximum likelihood phylogeny constructed over 
the 13,785 genome alignment. Nei’s genetic diversity index was computed 
as pH = 1 − ∑i
I
i=1
2,where I is the count of distinct alleles at a position, and 
p i I= ( = 1, …, )i  is the frequency of allele i in the studied alignment. The 
average homoplasy count per locus per gene region and average Nei’s 
genetic diversity per gene region were computed by normalising the per 
locus values by gene length for all ORF and NSP according to the reference 
annotations of GISAID reference genome EPI_ISL_402124. Significant 
differences between all pairwise combinations of ORF/NSP was assessed 
using the Wilcoxon rank sum test implemented in compare_means() in the 
R package ggpubr v0.4.0 (Extended Data Table 3).
IFI27 qPCR
Total RNA from Tempus blood was extracted using the Tempus Spin 


























using the High-Capacity cDNA Reverse Transcription Kit (Applied 
Biosystems). Quantitative PCR was performed using the TaqMan™ 
Fast Advanced Master Mix (Applied Biosystems) on ABI StepOnePlus 
Real-Time PCR machine (Applied Biosystems). The following cycling 
conditions were used: 95 °C for 2 mins, followed by 40 cycles of 95 °C 
for 3 s and 60 °C for 30 s. IFI27 and GAPDH were amplified using the 
TaqMan Gene Expression Assay probes-Hs01086373_g1 (IFI27) and 
Hs02786624_g1 (GAPDH) respectively. GAPDH was used as a house-
keeping gene control. Unexposed pre-pandemic control HCW cohort 
for qPCR described previously57
Correlogram plot
A pairwise correlation matrix between variables was calculated and 
visualised as a correlogram using corrplot (https://github.com/taiyun/
corrplot) in R version 3.5.3 with R studio version 1.0.153. Spearman’s 
rank correlation coefficient r is indicated by the size and colour of 
the circles. Only correlations with a p < 0.05 are shown. Variables are 
ordered by hierarchical clustering.
Statistics and reproducibility
Data was assumed to have a non-Gaussian distribution and nonpara-
metric tests were used throughout. For single paired and unpaired com-
parisons Wilcoxon matched-pairs signed rank test and a Mann-Whitney 
U test were used. For multiple unpaired comparisons Kruskal-Wallis 
one-way ANOVA with Dunn’s correction was used. For correlations, 
Spearman’s r test was used. A p value <0.05 was considered significant. 
Prism v. 7.0e and 8.0 for Mac was used for analysis. Details are provided 
in figure legends.
Data reporting
Power calculations were used to estimate the sample size needed for 
week 16 sub-study (see above). No statistical methods were used to 
predetermine sample size. For all assays samples from each cohort 
were run in parallel to reduce the impact of inter-batch technical vari-
ation. IFNγ-ELISpot assays were performed on HCW cohorts prior to 
unblinding of group (laboratory-confirmed infection or SN-HCW). 
Other experiments were not randomized and the investigators were 
not blinded to allocation during experiments and outcome assessment.
Reporting summary
Further information on research design is available in the Nature 
Research Reporting Summary linked to this paper.
Data availability
All data analysed during this study are included in this published arti-
cle (and its supplementary information files). Custom scripts used to 
perform the homology searches, heatmap visualisation and permu-
tation testing are hosted on GitHub (https://github.com/cednotsed/
tcell_cross_reactivity_covid.git). Genomic data analysed was obtained 
from the publicly available NCBI Virus database and, following regis-
tration, from the GISAID EpiCoV repository. The datasets generated 
during and/or analysed during the current study are available from 
the corresponding author on reasonable request. Correspondence 
and requests for materials should be addressed to MKM or LS. Source 
data are provided with this paper.
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Extended Data Fig. 1 | SARS-CoV-2 immunity in seronegative HCW – 
authentic virus neutralisation and T-cell response in those with NP1+NP2 
responses. a, authentic virus neutralisation (Wuhan Hu-1). b, Example plots  
of SARS-CoV-2 spike memory B cell (MBC) staining (gated on: lymphocytes/
singlets/Live, CD3-CD14-CD19+/CD20+, excluding CD38hi, IgD+ and 
CD21+CD27- fractions) and frequency of SARS-CoV-2 spike-specific MBC in 
pre-pandemic or SN-HCW (wk16; as a percentage of total MBC). Bars, median.  
c, Proportion of cohorts with T-cell responses to NP1 and/or NP2 subpools.  
d, Magnitude of T-cell response coloured by viral protein and e, summed 
response to RTC and structural regions in SN-HCW with T-cells reactive against 
both NP1 and NP2 and against one of or neither NP1 or NP2 pools at wk16. 
Kruskal-Wallis with Dunn’s correction. Bars, geomean. a-e, COVIDsortium 












































RTC r = -0.105 p = 0.668 ns (n=19)

























































































































nAb IC50 >50 (n = 64)
RTC Structural
p = 0.040*
No nAb (IC50<50, n = 7)
d. lab-confirmed infection r = 0.653 p <0.0001**** (n=74)
pre-pandemic r = 0.620 p <0.0001**** (n=53)

































Extended Data Fig. 2 | T-cell responses to RTC and structural regions of 
SARS-CoV-2 by cohort. a, T-cell response to Flu, EBV and CMV (FEC) MHC class 
I restricted peptide pool. b, E gene RT-PCR cycle threshold value vs.  
magnitude of T-cell response to RTC or structural proteins in HCW with 
laboratory-confirmed infection. c, Magnitude of T-cell response to RTC vs. 
structural regions. d, Magnitude of T-cell response to RTC (top) and structural 
regions (bottom) coloured by specificity. e, Magnitude of T-cell response in 
laboratory-confirmed infection group in HCW with or without detectable nAb 
at wk16. f, T-cell response to RTC coloured by protein in laboratory-confirmed 
infection group ordered by magnitude. HCW lacking neutralising antibodies 
highlighted by arrows below. a-f, IFNγ-ELISpot wk16. a, Red lines, geomean.  
e, Bars, geomean. b-c Spearman r. a,d Kruskal-Wallis ANOVA with Dunn’s 
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Extended Data Fig. 3 | Functional and proliferative SARS-CoV-2 specific 
T-cells in seronegative HCW. a, (Upper) Example gating of CTV stained PBMC 
after 10-day peptide stimulation: Lymphocytes (SSC-A vs. FSC-A), single cells 
(FSC-H vs. FSC-A), Live cells (fixable live/dead-), CD3+, CD4+ or CD8+. Second 
row: Gated on CD8+ showing cytokine/intracellular protein combinations. 
Response to immunodominant MHC class I-restricted peptide pool against Flu, 
EBV, CMV (FEC) in SN-HCW. (Lower) example CTV and IFNγ staining in a 
SN-HCW (gated on CD4+ [black] or CD8+ [blue] T-cells, percentage CTVloIFNγ+ 
shown). b, Correlation between the magnitude of T-cells responses to 
SARS-CoV-2 pools or FEC after 10-day in vitro expansion (% dual staining for two 
anti-human IFNγ mAb clones, responses <0.1% of CD3 post-expansion 
excluded) and ex vivo IFNγ-ELISpot in SN-HCW. Spearman r. c, Example plots of 
dual cytokine or activation marker staining of SARS-CoV-2-specific T-cells in an 
SN-HCW after 10-day expansion with peptide pools (proliferating T-cells 
become CTVlo as they divide and dilute out marker). SARS-CoV-2-specific 
T-cells highlighted in red (CD4+ CTVloIFNγ+). Percentage of CD4+ shown.  
d, polyfunctionality of CD4+ and CD8+ T-cells targeting the RTC or structural 
regions of SARS-CoV-2 or FEC peptide pool (proportion of cytokine producing 
T-cells that co-producing a given number of cytokines after 10-day peptide 
stimulation). Pie base, mean. Pie arcs show proportion of cells producing a 
given cytokine. e, Proportion of SARS-CoV-2-specific T-cells (CTVloIFNγ+) that 
are CD4+ or CD8+ after 10-day expansion (the protein specificity is listed 
above, donor ID (a-l, corresponding to raw data in Extended Data Table 2) and 










































































































































































































Extended Data Fig. 4 | Slope and variance of IFI27 signal in seronegative 
HCW. a, Subsetting SN-HCW group into those with weak (n=5, <50 SFC/106 
PBMC) or strong (n=20, >50 SFC/106 PBMC) RTC-specific T-cell responses at 
wk16. b, Slope and c, variance of IFI27 signal (wk0-5) in SN-HCW with weak (n=5) 
or strong (n=15) RTC-specific T-cell responses at wk16. d, Correlation matrix of 
variables for SN-HCW (colour and size of dots represent spearman’s r, only 
correlations p<0.05 shown; peak IFI27 signal from wk0-5, T-cell responses at 
wk16 to proteins, regions [RTC or structural], or total SARS-CoV-2 response). 



































































































































Extended Data Fig. 5 | Diversity along SARS-CoV-2 genome. a, Radial 
phylogeny of SARS-CoV-2 sequence diversity (611,893 genomes) with the 
13,785 accessions subsampled for diversity analysis shown in red. b, Genetic 
diversity (Nei’s genetic diversity index) at individual nucleotides along the 
SARS-CoV-2 genomes, together with the density of polymorphic nucleotides 
over an 100-nucleotide sliding window shown in grey shading (right y-axis) and 
c, Homoplasies (recurrent mutational emergences) at individual nucleotides, 
together with the density of the number of homoplasies recorded over an 
100-nucleotide sliding window shown in grey shading (right y-axis). d, Mean 
number of homoplasies across a given protein. Viral proteins not assayed for 



















































Extended Data Fig 6 | Cross-reactive coronavirus-specific T-cells in 
seronegative HCW. a, Example 2D-mapping matrix after 10-day expansion 
with NSP12-3 peptide pool in an SN-HCW (antigen-specific, CTVloIFNγ+; 
percentage of CD4+ or CD8+ shown). b, Alignment of Coronaviridae consensus 
sequences at immunogenic 15mers peptides (Extended Data Table 4). 
Conserved amino acids in yellow. c, (left) Example gating (lymphocytes 
(SSC-A,FSC-A)/singlets(FSC-A,FSC-H)/Live(Live-dead-)/CD3+CD19-/CD8+CD4-/
CD56-; example of staining in HLA-mismatched donor and fluorescence minus 
one for pentamer shown) and (right above) pentamer stains of PBMC from 
SN-HCW at wk16-26 ex vivo (co-staining of pentamers loaded with SARS-CoV-2 
peptide KLWAQCVQL and HKU1 peptide KLWQYCSVL) and (right below) after 
10-day expansion with SARS-CoV-2 peptide or HKU1 peptide (stained with 
SARS-CoV-2 peptide loaded pentamer). Percentage of CD8+ shown.  
d, Alignment of Coronaviridae sequences at HLA-A*02-restricted epitope in 
NSP7 (left) and magnitude of CD8+ T-cell response (CTVloIFNγ+) after 10-day 
expansion with HCoV variant sequence peptides as a percentage of response 
with SARS-CoV-2 sequence peptide (middle) or absolute percentage of total 
CD8+ (right). e, Example plot of CTV vs. IFNγ after 10-day expansion with 
SARS-CoV-2 or HCoV sequence 9-mer peptides (gated on lymphocytes/
singlets/live cells/CD3+/CD56-CD4-/CD8+). f, Alignment of Coronaviridae 
sequences at B*035-restricted epitope in NSP12 (left), magnitude of CD8+ 
T-cell response (CTVloIFNγ+) after 10-day expansion with HCoV variant 
sequence peptides as a percentage of response with SARS-CoV-2 sequence 
peptide (middle) or absolute percentage of total CD8+ (right). d,f, Conserved 
amino acids in yellow. d-f, SN-HCW wk16. a, c-f, COVIDsortium HCW cohort.  

























Extended Data Fig. 7 | Anti-spike IgG to human endemic coronaviruses. 
Anti-spike IgG titres were measured post-infection (wk8, time of peak 
SARS-CoV-2 S1 IgG seropositivity in COVIDsortium HCW cohort) in HCW with 
laboratory-confirmed infection (n=20), and post-exposure (wk8) in SN-HCW 
with weak (<50 SFC/106 PBMC, n=19) or strong RTC-specific T-cell response at 



















































Extended Data Fig. 8 | In vivo expansion of pre-existing SARS-CoV-
2-reactive T-cells post-infection or post-exposure. a, Change in magnitude 
of T-cell response between pre-pandemic and post-infection (upper panel: all 
proteins, lower panel: NSP12) in seropositive close contacts of cases.  
b, Summary data for paired pre-pandemic and post-exposure NSP12 and Flu/
EBV/CMV (FEC) responses in seronegative close contacts of infections. Below; 
example ELISpot well images from a seronegative close contact (NSP12-4: 
pre-pandemic 45 and post-exposure 95 SFC/106 PBMC). c, Change in magnitude 
of T-cell response between pre-pandemic and post-exposure samples (upper 
panel: all proteins, lower panel: NSP12) from seronegative close contacts of 
cases. d, Summary data for NSP12 and FEC responses in SN-HCW (sub-group 
with the top RTC response at wk16, n=19, Extended Data Fig. 4a). e, Summary 
data and f, change in magnitude of T-cell responses for individual HCW to NSP7 
(15 peptide pool) or a single subpool from NSP12 and NSP13 between baseline 
and post-exposure in SN-HCW (wk16-26, 29 responses from 13 SN-HCW).  
g, Change in magnitude of T-cell response to individual 9-15mer peptides pre- 
and post-exposure in SN-HCW (wk16-26, 11 responses from 9 SN-HCW).  
h, Example plots of CTVlo IFNγ+ SARS-CoV-2-specific T-cells after 10day expansion  
of PBMC from baseline and wk16 with peptide #166 (YVYLPYPDPSRILGA) or 
unstimulated in an HLA-B*51+ SN-HCW (gated on CD8+, percentage of CD8+ 
shown, gating strategy Extended Data Fig. 3a). i, Proportion of SN-HCW with 
NP1 + NP2-reactive T-cells grouped by those with and without newly detected 
or expanded NSP12 responses at wk16, Fig. 4b. j, Correlation between the 
fold-change in NSP12 between recruitment and wk16 and total response to RTC 
or structural proteins at wk16 in SN-HCW. Dotted line at 2-fold increase. k, The 
breadth of the NSP12-specific T-cell response (number of subpools recognised, 
pre-pandemic or wk16). l Change in magnitude of the T-cell response to NSP12 
between baseline (open circles) and wk16 (closed circles) in SN-HCW and HCW 
with laboratory-confirmed infection. Percentage of responders shown below. 
m, Change in magnitude of NSP12-specific T-cell response between 
pre-pandemic and post-infection in HCW with laboratory-confirmed infection. 
a,c,f-g,m, Expanded, >2-fold increase or >35 SFC/106 PBMC increase. a, Red line 
mean, d-e,I, Red line/bars, geomean. k, red line, median. b,d,e Wilcoxon test.  
l, Mann-Whitney (unpaired) and Wilcoxon (paired) tests. k, Kruskal-Wallis with 
Dunn’s correction. j, Spearman r. a-c, Contact cohort, Extended Data Table 5. 


























Extended Data Table 1 | Cohort Demographics




















































Extended Data Table 3 | SARS-CoV-2 Neis genetic diversity and number of homoplasies per site per gene region



















































Extended Data Table 5 | Demographics and sampling of Close Contact medical student/laboratory staff cohort
*Household contact with case-defining symptoms but no PCR confirmation available early 2020. Expanded = >2 fold or >35 SFU/106 PBMC increase in NSP12 response from pre-pandemic to 
post-exposure or infection time point.
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Reporting Summary
Nature Research wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency 
in reporting. For further information on Nature Research policies, see Authors & Referees and the Editorial Policy Checklist.
Statistics
For all statistical analyses, confirm that the following items are present in the figure legend, table legend, main text, or Methods section.
n/a Confirmed
The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement
A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
The statistical test(s) used AND whether they are one- or two-sided 
Only common tests should be described solely by name; describe more complex techniques in the Methods section.
A description of all covariates tested
A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons
A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) 
AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
For null hypothesis testing, the test statistic (e.g. F, t, r) with confidence intervals, effect sizes, degrees of freedom and P value noted 
Give P values as exact values whenever suitable.
For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings
For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes
Estimates of effect sizes (e.g. Cohen's d, Pearson's r), indicating how they were calculated
Our web collection on statistics for biologists contains articles on many of the points above.
Software and code
Policy information about availability of computer code
Data collection A complete masked alignment was downloaded from the GISAID EpiCoV database on 26/7/2021 together with a GISAID Audacity 
phylogeny comprising 611,893 accessions. The alignment was subsampled to include 800 of each defined NextStrain phylogenetic clade, 
as provided by GISAID metadata. For clades containing less than 800 accessions all representatives of that clade were included resulting 
in a comprehensive sampling over the global phylogeny of 13,785 accessions encompassing the genomic diversity of SARS-CoV-2 to date 
(Supplementary Table 4, Extended Data Fig. 5). 
Data analysis Software used for data/statistical analysis: FlowJo v.10.7.1; FACSDIVA v9.0; Prism 7.0e and 9.0; Excel v.16.16.09; R version 3.5.3 with 
RStudio Version 1.0.153 for Mac. 
 
Custom scripts used to perform the homology searches, heatmap visualisation and permutation testing are hosted on GitHub  
(https://github.com/cednotsed/tcell_cross_reactivity_covid.git).  Correlogram was produced using corrplot in R (https://github.com/
taiyun/corrplot). Polyfunctionality was visualised using SPICE (version 6.0) and pestle (version 2.0), available at https://niaid.github.io/
spice/. MUSCLE algorithm with default parameters and percentage identity was calculated in Geneious Prime 2020.1.2. Alignment figures 
were made in Snapgene 5.1 (GSL Biotech).
For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors/reviewers. 
We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Research guidelines for submitting code & software for further information.
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Policy information about availability of data
All manuscripts must include a data availability statement. This statement should provide the following information, where applicable: 
- Accession codes, unique identifiers, or web links for publicly available datasets 
- A list of figures that have associated raw data 
- A description of any restrictions on data availability
All data analysed during this study are included in this published article (and its supplementary information files). Genomic data analysed was obtained from the 
publicly available NCBI Virus database and, following registration, from the GISAID EpiCoV repository (full list and metadata available at: 10.6084/
m9.figshare.16607423). The datasets generated during and/or analysed during the current study are available from the corresponding author on reasonable 
request. Correspondence and requests for materials should be addressed to MKM or LS.   
 
Protein sequences for SARS-CoV-2 ORF1ab (accession numbers: QHD43415.1, NP_828849.2, YP_009047202.1, YP_009555238.1, YP_173236.1, YP_003766.2 and 
NP_073549.1) and for HCoV (accessions listed in Supplementary Table 1, NCBI Virus using 245 the taxid: 1118 together with accompanying metadata) were 
downloaded from the NCBI database (https://www.ncbi.nlm.nih.gov/). 
Field-specific reporting
Please select the one below that is the best fit for your research. If you are not sure, read the appropriate sections before making your selection.
Life sciences Behavioural & social sciences  Ecological, evolutionary & environmental sciences
For a reference copy of the document with all sections, see nature.com/documents/nr-reporting-summary-flat.pdf
Life sciences study design
All studies must disclose on these points even when the disclosure is negative.
Sample size Sample sizes are given for each figure throughout the paper when individual dots are not shown. Power calculations were performed prior to 
week 16 sub-study sampling to determine the sample size needed to test the hypothesis that HCW with pre-existing T cell responses are 
enriched in exposed uninfected group at a range of incidence of infection, assuming 50% of cohort had pre-existing T cell responses. Sample 
sizes of 18-64 per group were estimated. An age, sex and ethnicity matched nested substudy was designed within the larger (n=731) parent 
study and 129 attended for 16 week sampling including high volume PBMC isolation. Sample size can vary across figure panels depending on 
which stimulations were performed (limited by number of PBMC recovered). Cohort sizes given in Figure 1a.
Data exclusions Classification of HCW and study participants into cohorts is defined in methods as are any specific exclusions of data points from individual 
graphs. Two HCW in the seronegative cohort (negative for NP and S1 antibodies wk 0-16) had nAb titres just above the threshold IC50 of 50 
were excluded from further analyses (exclusion criteria not pre-established, determined using unexposed pre-pandemic and PCR+ samples). 
No other HCW or individual samples were excluded after data was generated. 
Replication Replication for each assay are described in the methods. Briefly, per sample unstimulated controls were run in duplicate for ELISpot data with 
no data excluded due to outliers. Due to limited sample availability ELISpots were only repeated on a small number of pre-pandemic samples. 
Replicates were successful. CTV proliferation assays were repeated and experimental replicates performed on a subset of individuals 
successfully. Duplicates were used for S1 ELISAs with no outliers excluded. qPCR was repeated on a subset of individuals successfully. 
Neutralization assays were preformed over a wide range of dilutions in duplicate. 
Randomization Experiments were performed with protocols optimised to reduce batch variation and to ensure mixing of experimental groups across batches 
e.g Flow cytometer parameters were consistent between runs (No MFI comparisons were performed, only gating and percentage of parent). 
Samples from pre-pandemic, seronegative HCW and seropositive HCW were ran in parallel on ELISpot plates.  
 
Laboratory-confirmed infection was determined by weekly nasopharyngeal RNA stabilizing swabs and reverse transcriptase polymerase chain 
reaction (RT-PCR; Roche cobas SARS-CoV-2 test, Envelope [E] gene) and antibody assay positivity (Spike protein 1 IgG Ab assay, EUROIMMUN) 
and anti-nucleocapsid total antibody assay (ROCHE). The seronegative health care worker group were matched for demographics and 
exposure to the laboratory-confirmed infected group and was defined by negativity by these three tests at all 16 time points as well as 
negative for neutralising antibodies at week 16 and at selected prior time points as indicated. Unexposed pre-pandemic samples were not 
matched for demographics (Demographics given in Extended Data Table 1). 'Close-contact cohort' self-identified as having had close contact 
(household contact or alert by NHS test-and-trace app of close contact with a confirmed case) were divided into seropositive or seronegative 
(determined by S1 ELISA), Extended Data Table 4.
Blinding IFNg-ELISpot assays were performed on HCW cohorts prior to unblinding of group (laboratory-confirmed-infection or seronegative). Other 
experiments were not randomized and the investigators were not blinded to allocation during experiments and outcome assessment, 
however, experimental set-up and controls ensured accurate replication across technical replicates (see above and methods). 
Reporting for specific materials, systems and methods
We require information from authors about some types of materials, experimental systems and methods used in many studies. Here, indicate whether each material, 
system or method listed is relevant to your study. If you are not sure if a list item applies to your research, read the appropriate section before selecting a response. 
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Materials & experimental systems













Antibodies used Detailed information regarding all antibodies and other fluorescent agents used in this study are listed in the methods with 
manufacturer, clone, and dilution used.  
ELISpot - human anti-IFNγ Ab (1-D1K, Mabtech; 10 μg/ml), biotinylated IFN-γ detection antibody (7-B6-1, Mabtech; 1μg/ml).  
 
FACS: Memory B cell Panel: CD3 Bv510 (Biolegend, clone OKT3, 1:200), CD11c FITC (BD Biosciences, clone B-ly6, 1:100), CD14 
Bv510 (Biolegend, clone M5E2, 1:200), CD19 Bv786 (BD bioscience, clone HIB19, 1:50), CD20 AlexFluor700 (BD biosciences 2H7, 
1:100), CD21 Bv711 (BD biosciences, clone B-ly4, 1:100), CD27 BUV395 (BD biosciences, clone L128, 1:100), CD38 Pe-CF594 (BD 
biosciences, clone HIT2, 1:200), IgD Pe-Cy7 (BD biosciences, clone IA6-2, 1:100). 
 
FACS: CTV assay: IL-2 PerCp-eFluor710 (Invitrogen, clone MQ1-17H12, 1:50), TNFα FITC (BD bioscience, clone MAb11, 1:100), 
CD8α BV785 (Biolegend, clone RPA-T8, 1:200), IFN? BV605 (BD biosciences, clone B27, 1:100), IFN? APC (Biolegend, clone 4S.B3, 
1:50), CD3 BUV805 (BD biosciences, clone UCHT1, 1:200), CD4 BUV395 (BD biosciences, clone SK3, 1:200), CD154 (CD40L) Pe-
Cy7 (Biolegend, clone 24-31, 1:50), MIP-1-β PE (BD biosciences, clone D21-1351, 1:100).  
 
FACS:MHC class I pentamer panel: CD3 BUV805 (BD biosciences, clone UCHT1, 1:200), CD4 BUV395 (BD biosciences, clone SK3, 
1:200), CD56 Pe-Cy7 (BD biosciences, NCAM16.2, 1:100), CD8α Alexa700 (Biolegend, RPA-78, 1:200), post-expansion CD19 
Bv786 (BD biosciences, HIB19, 1:100).
Validation All antibodies and MHC class I pentamers were purchased from well established manufacturers and were validated by the 
vendor for species and target. e.g. BD biosciences, Biolegend, and Invitrogen antibodies are tested in Knock-out/knock-in primary 
model systems to ensure biological accuracy in ISO 9001 certified facilities. Side-by-side lot comparisons are performed. Details 
of antibody clones have been included for cross-referencing of manufacturing company specification/validation processes. We 
further validated antibodies by titration to optimal concentrations and by using positive controls where possible (e.g. using 
populations known to express a certain marker or by polyclonal stimulation). MHC class I pentamers were tested in HLA-
mismatched individuals to assess background staining and on T cell clones expanded with cognate peptide.  
 
Fluorescence minus one stains were used to define gates in Flowjo for all FACS assays . Positive (SARS-CoV-2 laboratory-
confirmer infected) and negative controls (unexposed pre-pandemic samples) were included in each run for memory B cell 
staining.  Positive control wells were used in CTV stains to ensure accurate staining of cytokines and CTV staining was checked on 
day 0 before stimulation. Unstimulated control wells treated as peptide wells (e.g. addition of DMSO) were run per biological 
sample for CTV proliferation assays and ELISpots (in duplicate for ELISpots) and all data is presented as background subtracted as 
described in the methods.  
Human research participants
Policy information about studies involving human research participants
Population characteristics Age, sex and ethnicity of cohorts are provided in Extended Data Table 1 and 4, and in detail for the COVIDsortium in Augusto et 
al Wellcome Open Research 2020. Substudy recruitment for all wk16 data presented was performed on a cohort of  
seronegative HCW matched for age, sex, and ethnicity with a group of laboratory-confirmed infected HCW. 
Recruitment Recruitment is described in details in Augusto et al Wellcome Open Research and in the methods section. Adult (>18 years) 
hospital HCWs who were fit and well to attend work in any role and across a range of clinical areas, were invited to participate 
via hospital email, posters, staff meetings, training sessions and participant information leaflets (see https://covid-
consortium.com). No other inclusion or exclusion criteria were considered.The “COVID-19 Immune Protection and Pathogenesis 
in Healthcare Worker Bioresource” (NCT04318314) uses a prospective cohort design (Figure 1). The study consists of 
questionnaires and biological samples (blood samples, nasal swabs ± saliva) performed at all visits: baseline, weekly follow-ups 
for 15 weeks, and visits at 6 and 12 months. An age, sex and ethnicity matched nested sub-study was designed within the larger 
(n=731) parent study and 129 attended for 16-week sampling including high volume PBMC isolation. For the 'close-contact 
cohort' medical students previously enrolled in a BCG vaccine trial (UCL Ethics Project ID Number: 13545/001) were invited to 
participate by email and were re-consented. 
Ethics oversight The COVIDsortium bioresource was approved by the ethical committee of UK National Research Ethics Service (20/SC/0149) and 
registered on ClinicalTrials.gov (NCT04318314). The cohort of medical students and laboratory staff was approved by UCL Ethics 
(Project ID Number: 13545/001) and pre-pandemic healthy donor samples were collected and cryopreserved before August 
2019 under ethics numbers 11/LO/0421. All subjects gave written informed consent and the study conformed to the principles 
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of the Helsinki Declaration.
Note that full information on the approval of the study protocol must also be provided in the manuscript.
Clinical data
Policy information about clinical studies
All manuscripts should comply with the ICMJE guidelines for publication of clinical research and a completed CONSORT checklist must be included with all submissions.
Clinical trial registration ClinicalTrials.gov (NCT04318314)
Study protocol ClinicalTrials.gov (NCT04318314), Augusto et al Wellcome Open Research 2020. 
Data collection Data collection is described in detail in Augusto et al Wellcome Open Research and in the methods section. The “COVID-19 
Immune Protection and Pathogenesis in Healthcare Worker Bioresource” (NCT04318314) uses a prospective cohort design. The 
study consists of questionnaires and biological samples (blood samples, nasal swabs ± saliva) performed at all visits: baseline, 
weekly follow-ups for 15 weeks, and visits at 6 and 12 months. Recruitment was initially at St Bartholomew’s Hospital, London, 
UK (400 HCWs recruited between 23rd and 31st March 2020, just before the peak of new daily cases in London, which happened 
on the 2nd April, with 1,022 new cases confirmed). To improve statistical power for downstream analyses, we expanded the 
target sample size to n=1,000 and extended recruitment on 17th April 2020 to other local sites: Royal Free NHS Hospital Trust 
(large teaching hospital with specialist expertise in infectious diseases). Baseline: Participants complete a baseline questionnaire 
including standard variables related to demographics and exposures. These included occupation, household details, smoking 
status, physical activity, anthropometry, medical history (including vaccination history, current medication and dietary 
supplements), occupational exposure (including specific clinical areas and access to/use of personal protective equipment [PPE]), 
travel history, previous COVID-19 symptoms, proven contact with SARS-CoV-2 infected individuals, and any prior testing for 
SARS-CoV-2 infection. Follow-up: Following recruitment (baseline visit), if fit and well to attend work, participants would 
undertake in-person weekly questionnaires using research electronic data infrastructure (REDCap v8.5.22)16 to capture 
occupational metadata, new SARS-CoV-2 exposure, symptoms and test results, and biosample collection.




The axis labels state the marker and fluorochrome used (e.g. CD4-FITC).
The axis scales are clearly visible. Include numbers along axes only for bottom left plot of group (a 'group' is an analysis of identical markers).
All plots are contour plots with outliers or pseudocolor plots.
A numerical value for number of cells or percentage (with statistics) is provided.
Methodology
Sample preparation Detailed sample preparation is given in methods. All FACS was performed on frozen and thawed PBMC isolated by density 
gradient separation. Peripheral blood mononuclear cells (PBMC) were isolated from heparinized blood samples using Pancoll 
(Pan Biotech) or Histopaque®-1077 Hybri-MaxTM (Sigma-Aldrich) density gradient centrifugation in SepMate tubes (StemCell) 
according to the manufacturer’s specifications. Isolated PBMCs were cryopreserved in fetal calf serum (FCS) containing 10% 
DMSO and stored in liquid nitrogen. 
Instrument BD biosciences LSRII and Fortessa-X20 flow cytometers. 
Software FACS DIVA version 9.0 was used on instrument and exporting .fcs files were analysed in FlowJo version 10.7.1 (TreeStar)
Cell population abundance PBMC were stained and run without sorting or enrichment. 
Gating strategy Example gating strategy for CTV proliferation and mapping FACS experiments is given in Extended Data Figure 3a. Example plots 
are given in Fig. 2c, Fig 3g, and Extended Data Fig 3d and Extended Data Fig. 6a. Data is reported as a percentage of 
lymphocytes/singlets/live/CD3+/CD4+ or CD8+ defining antigen specificity by production of IFNg and CTV dilution. For memory B 
cell stains example plots are given in Extended Data Figure 1b and details of cutoff and assay validation are given in Jeffery-Smith 
et al BioRxiv 2021. Gating is described in legends: MBC expressed as a percentage of lymphocytes, singlets, Live, CD3-CD14-CD19
+, CD20+, excluding CD38hi, IgD+ and CD21+CD27- fractions. MHC class I Pentamer gating and example plots in Extended Data 
Figure 6c. 
Tick this box to confirm that a figure exemplifying the gating strategy is provided in the Supplementary Information.
